Piper Jaffray analyst Thomas Gunderson views Bloomberg's report that Pfizer (PFE) may be considering a sale of the infusion pump division of the recently acquired Hospira as neutral for ICU Medical (ICUI). Hospira has traditionally been ICU's largest customer, which has some worrying that if the infusion pumps are sold once again, the business could be at risk, Gunderson tells investors in a research note. He believes, however, that a Pfizer divestment could bring some upside to ICU since the infusion pump business is not in the pharma giant's "wheelhouse." Gunderson keeps an Overweight rating on ICU Medical with a $129 price target.

Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.